Company / Gross Profit
Haemonetics Gross Profit History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Profit
$749.0M
FY2024
5-year range
$505.5M / $749.0M
FY2020-FY2024
Trend
+8.3%
vs FY2023
Sector context
#48 of 95
Health Care
What the data says
At $749M, Haemonetics's gross profit ranks #48 of 95 in the Health Care sector. Gross Profit has increased for 4 consecutive years, from $398M in FY2020 to $749M in FY2024.
Based on SEC 10-K filings.
$749M in FY2024 with a 5-year CAGR of +9.1%.
Improved from $615M to $749M over the past 2 years.
Health Care sector context is included.
Gross Profit over time
Growth rates
- 3-Year CAGR
- +14.0%
- 5-Year CAGR
- +9.1%
- 10-Year CAGR
- -
Sector benchmark
#48 of 95 in Health CareTop 51% of 95This company $749.0M Sector average $2.0B
▼
-62.6% below sector average
Key checks
Key Insights
- Haemonetics's gross profit has grown for 4 consecutive years.
- 5-year CAGR of +9.1%, indicating consistent growth.
- In FY2024, gross profit increased 8.3% year-over-year.
- Ranks #48 out of 95 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score 0.44 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross ProfitValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $749.0M | +8.3% |
| FY2023 | $691.5M | +12.4% |
| FY2022 | $615.1M | +21.7% |
| FY2021 | $505.5M | +27.1% |
| FY2020 | $397.8M | -17.9% |
| FY2019 | $484.5M | +16.0% |
| FY2018 | $417.5M | +1.4% |
| FY2017 | $411.9M | +8.8% |
| FY2016 | $378.5M | -6.8% |
As of FY2024 · SEC 10-K · Updated Mar 28, 2026